---
ver: rpa2
title: 'Diff4VS: HIV-inhibiting Molecules Generation with Classifier Guidance Diffusion
  for Virtual Screening'
arxiv_id: '2407.15880'
source_url: https://arxiv.org/abs/2407.15880
tags:
- molecules
- drug
- generative
- molecule
- screening
- transformers
- self-attention
- retrieval-augmented-generation
- instruction-tuning
- parameter-efficient-finetuning
- mixture-of-experts
- chain-of-thought
core_contribution: Diff4VS combines classifier guidance diffusion with ligand-based
  virtual screening to generate HIV-inhibiting molecules, addressing the challenge
  of identifying new compounds for AIDS treatment. The method trains a classifier
  on HIV molecule data to guide the diffusion model in generating drug-like candidates.
---

# Diff4VS: HIV-inhibiting Molecules Generation with Classifier Guidance Diffusion for Virtual Screening

## Quick Facts
- arXiv ID: 2407.15880
- Source URL: https://arxiv.org/abs/2407.15880
- Reference count: 33
- Diff4VS achieves 104.62% HIV Drug Index, outperforming other generative models

## Executive Summary
Diff4VS introduces a novel approach to generate HIV-inhibiting molecules using classifier guidance diffusion for virtual screening applications. The method combines discrete diffusion models with an extra classifier trained on HIV molecule data to guide the generation process toward drug-like compounds. A new metric called DrugIndex is proposed to evaluate the ability of generative models to produce drug-like molecules, and experiments show Diff4VS significantly outperforms existing methods like charRNN, JT-VAE, and LatentGAN.

## Method Summary
Diff4VS employs discrete diffusion models with graph transformer architecture to generate molecular graphs. The method trains a separate classifier on HIV molecule data that provides gradient guidance during the reverse diffusion process, steering generation toward HIV-inhibiting properties. The classifier uses BCE loss and is integrated through FiLM conditioning layers. Generated molecules are evaluated using DrugIndex, which measures the ratio of drug-like molecules in generated sets versus training sets, and validated through virtual screening with GCN classifiers.

## Key Results
- Diff4VS achieves HIV Drug Index of 104.62%, outperforming charRNN (78.80%), JT-VAE (87.46%), and LatentGAN (94.19%)
- Using BCE loss function for classifier guidance yields 104.62% DrugIndex versus 84.17% with MSE loss
- Generated molecules show lower similarity to known drugs compared to real molecules, termed "Degradation" phenomenon

## Why This Works (Mechanism)

### Mechanism 1
Classifier guidance improves generation of HIV-inhibiting molecules by steering the diffusion process toward desired molecular properties. An extra classifier trained on HIV molecule data provides gradient information that guides the diffusion model during reverse denoising, increasing the proportion of generated molecules similar to known HIV drugs. The classifier uses BCE loss with gradient proportionality assumptions.

### Mechanism 2
DrugIndex metric effectively evaluates generative models' ability to produce drug-like molecules for virtual screening. It measures the ratio of drug-like molecules in generated sets versus training sets, providing pharmaceutical perspective on generation quality that QED alone cannot capture. Molecules with similarity > 0.5 to known drugs are considered candidates.

### Mechanism 3
Degradation phenomenon occurs because generative models struggle to produce specific molecular structures found in HIV-inhibiting drugs. When clustering HIV drug molecules by Morgan fingerprints, certain structural clusters are absent from generated molecules despite being present in training data, indicating structural generation limitations.

## Foundational Learning

- Discrete diffusion models for molecular graphs: Needed because molecular structures are inherently discrete (atoms and bonds) rather than continuous. Quick check: What distinguishes discrete diffusion from standard continuous diffusion models in molecular generation?

- Classifier guidance in diffusion models: Needed to steer the generation process toward molecules with desired properties. Quick check: How does classifier guidance modify the sampling process in diffusion models?

- Graph neural networks for molecular property prediction: Needed to evaluate generated molecules through virtual screening. Quick check: What graph neural network architectures are commonly used for molecular property prediction tasks?

## Architecture Onboarding

- Component map: Diffusion model (graph transformer) -> Classifier (graph transformer) -> GCN models for virtual screening -> DrugIndex calculation -> k-means clustering for Degradation analysis
- Critical path: Training diffusion model → Training classifier → Guided sampling → Virtual screening with GCNs → DrugIndex evaluation
- Design tradeoffs:
  - Discrete vs continuous diffusion: Discrete better captures molecular discrete structures but requires different mathematical treatment
  - BCE vs MSE loss for classifier: BCE directly optimizes for classification accuracy, MSE might be more stable but less targeted
  - Classifier vs classifier-free guidance: Classifier guidance requires less training data but may introduce bias from classifier errors
- Failure signatures:
  - Low DrugIndex indicates failure to generate drug-like molecules
  - Degradation phenomenon indicates structural generation limitations
  - Low virtual screening accuracy suggests poor generation quality
  - Training instability in discrete diffusion due to discrete state space
- First 3 experiments:
  1. Train diffusion model on MOSES dataset without classifier guidance to establish baseline generation quality
  2. Train classifier on HIV-a dataset with BCE loss to verify guidance capability
  3. Generate molecules with and without classifier guidance and compare DrugIndex values to quantify improvement

## Open Questions the Paper Calls Out

### Open Question 1
How can we improve the training data for generative models to better capture specific molecular structures that are difficult to generate, such as aromatic rings? The paper identifies the "Degradation" phenomenon but does not provide solutions for improving training data to better capture these specific structures.

### Open Question 2
What are the theoretical limitations of using continuous approximations for discrete molecular structures in diffusion models, and how can these be addressed? The paper acknowledges these limitations but does not explore potential solutions or alternative theoretical approaches.

### Open Question 3
How can we develop more effective loss functions for classifier guidance in diffusion models to improve generation of drug-like molecules? The paper shows BCE loss works better than MSE but does not provide comprehensive analysis of different loss functions or their impact.

## Limitations
- The DrugIndex metric lacks validation against established benchmarks in the literature
- The "Degradation" phenomenon is described but not systematically quantified across different generative models
- Specific hyperparameter settings for the diffusion model and classifier guidance are not fully specified

## Confidence
- Diff4VS achieving 104.62% HIV Drug Index: Medium - The metric is novel and well-defined, but lacks external validation
- Classifier guidance mechanism effectiveness: Medium - The mechanism is theoretically sound but lacks ablation studies comparing guided vs non-guided generation
- Degradation phenomenon existence: Low-Medium - Limited to single cluster analysis without broader statistical validation across multiple structural features

## Next Checks
1. Replicate the DrugIndex calculation using an independent dataset of HIV-inhibiting molecules to verify the 104.62% improvement claim
2. Perform ablation study comparing Diff4VS with and without classifier guidance to isolate the contribution of the guidance mechanism
3. Extend the Degradation analysis to multiple structural clusters and include statistical tests to determine if the observed differences are significant beyond the single cluster 13 example